Kasabach Merritt Syndrome

• Kasabach Merritt Syndrome (KMS) is a rare, life-threatening blood clotting disorder associated with rapidly growing vascular tumors.
• It primarily affects infants and young children, leading to severe thrombocytopenia and coagulopathy.
• Symptoms include a rapidly enlarging vascular lesion, bruising, petechiae, and signs of internal bleeding.
• Diagnosis relies on clinical presentation, imaging, and blood tests showing low platelet counts and clotting factor deficiencies.
• Treatment involves managing the vascular tumor and correcting the coagulopathy, often with medications and sometimes surgery.

What is Kasabach Merritt Syndrome?

Kasabach Merritt Syndrome (KMS) is a rare, life-threatening hematologic disorder characterized by the rapid enlargement of a vascular tumor, typically a kaposiform hemangioendothelioma (KHE) or tufted angioma, which leads to severe thrombocytopenia (low platelet count) and consumptive coagulopathy. This means that the growing tumor traps and destroys platelets and other clotting factors, impairing the body’s ability to form clots and stop bleeding. While rare, KMS is a serious condition that primarily affects infants and young children, often presenting within the first year of life. Its incidence is estimated to be less than 1 in 100,000 live births, according to studies on rare pediatric conditions.

Symptoms of Kasabach Merritt Syndrome

The Kasabach Merritt Syndrome symptoms are primarily related to the presence of the vascular tumor and the resulting blood clotting abnormalities. The most prominent sign is a rapidly growing vascular lesion, which can appear anywhere on the body, often on the limbs, trunk, or head and neck. These tumors are typically firm, warm to the touch, and may have a reddish-purple discoloration. Beyond the visible tumor, the critical symptoms stem from the severe coagulopathy.

Common symptoms include:

• Rapidly enlarging vascular lesion: A noticeable, often discolored, mass that grows quickly.
• Petechiae: Tiny, pinpoint red or purple spots on the skin, indicating bleeding under the skin due to low platelet counts.
• Ecchymoses: Larger areas of bruising, often appearing spontaneously or with minimal trauma.
• Bleeding: This can manifest as nosebleeds, gum bleeding, gastrointestinal bleeding, or, in severe cases, intracranial hemorrhage.
• Swelling and pain: The tumor itself can cause localized swelling and discomfort.
• Anemia: Due to chronic blood loss or sequestration within the tumor.
• Signs of internal bleeding: Such as abdominal distension, pallor, or neurological changes if bleeding occurs in vital organs.

Causes and Treatment for Kasabach Merritt Syndrome

The Causes of Kasabach Merritt Syndrome are directly linked to the development of specific vascular tumors, namely kaposiform hemangioendothelioma (KHE) or tufted angioma. These tumors are benign but locally aggressive and are characterized by abnormal proliferation of endothelial cells. While the exact trigger for their formation is not fully understood, they are believed to arise from somatic mutations in certain genes, rather than being inherited. These tumors act as a “sink” for platelets and clotting factors, leading to their rapid consumption and the subsequent development of the syndrome. It is important to note that KMS is not caused by trauma or infection, but rather by the unique characteristics of these specific vascular lesions.

Kasabach Merritt Syndrome treatment focuses on two main objectives: controlling the growth of the vascular tumor and correcting the severe coagulopathy. Treatment strategies are often multidisciplinary and tailored to the individual patient’s condition and the tumor’s location and size.

Common treatment approaches include:

• Pharmacological therapy: Corticosteroids are often used as a first-line treatment to reduce tumor size and inflammation. Vincristine, a chemotherapy agent, can be effective in shrinking the vascular tumor. Sirolimus (rapamycin), an immunosuppressant, has shown promise in inhibiting tumor growth and improving coagulopathy. Propranolol, a beta-blocker, is sometimes used for vascular anomalies, though its efficacy in KMS is still being studied compared to other treatments.
• Blood product transfusions: Platelets and fresh frozen plasma are often administered to correct thrombocytopenia and replenish clotting factors, especially before procedures or in cases of active bleeding.
• Embolization: A procedure where substances are injected into the blood vessels supplying the tumor to block blood flow, thereby reducing its size and activity.
• Surgery: In some cases, surgical removal of the tumor may be considered, especially if it is localized and accessible, or if other treatments are ineffective. However, surgery can be challenging due to the high risk of bleeding.
• Radiation therapy: Rarely used due to potential long-term side effects in children, but may be considered in severe, life-threatening cases where other treatments have failed.

The goal of treatment is to stabilize the patient’s blood counts, prevent life-threatening bleeding, and ultimately reduce the size and activity of the vascular tumor. Close monitoring by a team of specialists, including hematologists, oncologists, and interventional radiologists, is crucial for managing this complex syndrome.